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Abstract
Denosumab discontinuation is associated with a rapid increase in bone resorption and a decrease in bone mineral density.
Spontaneous vertebral fractures may occur as a side effect of the rebound of bone resorption. Cases of rebound-linked hyper-
calcemia have also been described, moderate in women with osteoporosis and breast cancer and severe in children receiving
oncological doses of denosumab. We report the case of an adult woman with primary hyperparathyroidism and moderate
hypercalcemia, treated with denosumab for osteoporosis, who developed severe hypercalcemia and spontaneous vertebral
fractures (SVFs) after denosumab discontinuation. An 86-year-old womanwith densitometric osteoporosis was treated for 3 years
with 60 mg of subcutaneous denosumab every 6 months. She was known to have primary hyperparathyroidism, with a serum
albumin-corrected calcium of 2.82 mmol/l (NV 2.15–2.5) at the end of denosumab effect. Nine months after the last denosumab
injection, she was hospitalized due to worsening overall health. Clinical evaluation revealed severe hypercalcemia (calcium
3.35 mmol/l). Very high values of bone turnover markers (BTMs) suggested a rebound effect due to denosumab discontinuation.
An X-ray showed multiple new SVFs. After injection of denosumab 60 mg, serum calcium rapidly decreased and BTMs were
dramatically reduced. A surgical approach by minimally invasive parathyroidectomy allowed for definite resolution of hyper-
parathyroidism and hypercalcemia. This case suggests that hypercalcemia can be a side consequence of denosumab discontin-
uation, which can become severe when other causes of hypercalcemia, such as primary hyperparathyroidism, are present.
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Introduction
Denosumab, a fully human monoclonal antibody that blocks
the receptor activator of nuclear factor k-B ligand (RANKL),
is a potent anti-resorptive osteoporosis treatment. Due to its
reversible mode of action, bone turnover markers (BTMs)
increase rapidly after its discontinuation, accompanied by a
quick loss of bone mineral density (BMD) [1]. Spontaneous
vertebral fractures (SVFs) have been described in this
situation and a causative link to the rebound of bone resorp-
tion has been suggested [2]. Cases of rebound-linked hyper-
calcemia have also been described after denosumab discontin-
uation, from completely asymptomatic [3, 4] to severe clinical
consequences [5–13]. Only two cases have been described in
patients with moderate symptoms treated with denosumab for
osteoporosis [4, 14]; all other patients had received
denosumab at high (oncological) and/or frequent (minimum
every 3 months) dosages.
We report the case of a patient who developed severe acute
hypercalcemia after discontinuation of denosumab 60mg giv-
en every 6 months for osteoporosis in the context of known
hyperparathyroidism.
Case report
An 86-year-old woman with hypercalcemia was diagnosed in
2013 in the context of primary hyperparathyroidism by her
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endocrinologist. At that time, she refused the proposed surgi-
cal treatment. Due to densitometric osteoporosis (lumbar
spine T-score, − 6.0 SD; femoral neck T-score, − 4.5 SD),
denosumab 60 mg was given subcutaneously every 6 months
from 2013 to October 2016 (last injection) with good but
insufficient effect (04.2015: lumbar spine T-score, − 5.4 SD;
femoral neck T-score, − 3.9 SD). The reason for the treatment
discontinuation is unknown. In April 2017, at the end of
denosumab efficacy (6 months post last injection), serum
albumin-corrected calcium (referred as calcium from here
on) level was 2.82 mmol/l (NV 2.15–2.50) and serum para-
thyroid hormone (PTH) level was 24.2 pmol/l (NV 1.3–9.3)
(Table 1). Treatment with cinacalcet 30 mg/day was intro-
duced and calcium decreased to 2.51 mmol/l 1 month later,
suggesting good control of hypercalcemia, but the cinacalcet
was lowered first and finally discontinued by the patient due
to digestive intolerance. It was reintroduced mid-July 2017
following a re-increase in calcemia (calcium 3.53 mmol/l).
At the end of July 2017, the patient was hospitalized due to
weight loss (5 kg, 15% body weight), malnutrition, and poor
health status (asthenia, confusion). Clinical evaluation revealed
severe hypercalcemia (calcium 3.35 mmol/l), with lower PTH
under cinacalcet (10.0 pmol/l). The serum 25-OH vitamin D
level was 77 nmol/l (NV 50–75). Initial treatmentwith hydration
and intranasal calcitonin only partially corrected calcium to
2.57 mmol/l, and then, despite cinacalcet maintaining low
PTH (6.5 pmol/l) calcemia increased again (calcium
3.11 mmol/l). She was at that point referred to our center.
Type I collagen c-terminal telopeptide (CTX) was high at
1777 ng/l (NV< 573), despite mild renal dysfunction (creatinine
97 μmol/l, NV 44–80 μmol/l; eGFR 50 ml/min/1.73 m2) sug-
gesting a rebound effect due to denosumab discontinuation. A
















07.04.2017 2.82 24.2* 77 77 6 months after denosumab
05.2017 Cinacalcet 30 mg initiation
30.05.2017 2.51 Cinacalcet reduction to 15 mg
13.07.2017 3.53 Cinacalcet had been discontinued by
patient, reintroduction at 30 mg
18.07.2017 3.11 10
29.07.2017 3.35 69 162 Hospitalization (calcitonin, i.v. hydration,
and cinacalcet 30 mg)
03.08.2017 2.57 Under whole treatment
07.08.2017 2.99 6.5* Under cinacalcet
18.08.2017 3.11 Under cinacalcet
21.08.2017 3.06 9.2* 111 1777/156 Denosumab injection
14.09.2017 2.79 20.9* 93 122/114
13.10.2017 2.58 31.7 65
14.11.2017 2.61 34.4
20.12.2017 2.62 81
08.02.2018 2.76 20.5# Denosumab injection
20.09.2018 2.77 16.8# 367/30 96 Denosumab injection
18.10.2018 2.63
18.01.2019 2.69 71 40/14
20.02.2019 2.76 28.7# 30/13 76.7 Parathyroidectomy
21.02.2019 2.44 7.5# Immediate post-surgery
26.02.2019 2.17 18.3* 40/9
18.03.2019 2.36 4.45# 87 27 / 18 Denosumab injection
11.04.2019 2.38
iCa, ionized calcium; cCa albumin-corrected calcium, normal values: 2.15–2.50 mmol/l; PTH, parathyroid hormone, normal values: 1.3–9.3 pmol/l or
*1.3–6.8 pmol/l, # values initially measured in ng/l, converted into pmol/l; creatinine, normal values: 44–80μmol/l;CTX, C-terminal telopeptide of type I
collagen, premenopausal women upper limit: 573 ng/l; P1NP, procollagen type 1 N-telopeptide, premenopausal women upper limit: 56.3 μg/l; 25-OH
vit D, 25-OH vitamin D, normal values > 75 nmol/l
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spinal X-ray showed three new SVFs. Denosumab treatment
was restored, and after a single 60 mg injection, serum calcium
rapidly decreased to 2.63 mmol/l. CTX decreased dramatically
to 122 ng/l. With the resumption of denosumab injections
(60 mg twice a year), calcemia remained stable between 2.60
and 2.80 mmol/l, without any other treatment. PTH levels in-
creased when calcemia was close to normal values. The patient
finally accepted surgical treatment for a parathyroid adenoma
identified by neck ultrasound and 99mTc-MIBI SPECT/CT
scintigraphy. Surgery resulted in calcium normalization in the
presence of denosumab treatment (Table 1).
Discussion
This case suggests that, in patients with known hypercalcemia
due to primary hyperparathyroidism, high bone remodeling
induced by denosumab discontinuation can elicit acute hyper-
calcemia with severe clinical consequences.
Denosumab discontinuation induces a rebound effect, with
BTMs rapidly increasing over baseline values after its discon-
tinuation, a quick loss of BMD, and an increased risk of SVFs.
During this period, hypercalcemia has also been recognized as
a consequence of high bone resorption, with most cases de-
scribed in children [3, 5–11, 15]. Affected children were
4 months to 15 years old, received 120 mg of denosumab (or
weight-adapted dosage) for 7 to 42 months, and developed
hypercalcemia from 7 weeks to 7 months after the last
denosumab injection (Table 2). In seven cases, there were dra-
matic consequences (hospitalization, bone pain, dehydration
with renal insufficiency, bradycardia). In order to normalize
calcium values, different management strategies were applied,
all including hydration and i.v. bisphosphonates (pamidronate,
zoledronate), as well as calcitonin, corticosteroids, furosemide,
or, in one case, resumption of denosumab [5]. In all cases,
multiple treatments, given for up to 4 weeks, were required to
control rebound hypercalcemia [4–7, 10–13, 15].
As the first cases were reported in children, it has been
suggested that rebound hypercalcemia was linked to increased
bone modeling and remodeling during the growing period
[10]. However, since 2018, three cases of severe hypercalce-
mia needing hospitalization (albumin-corrected calcium 3.10
to 3.59 mmol/l) 4–5 months after the last denosumab injection
have been published in adults. A 40-year-old man was treated
with denosumab 120 mg monthly for 4 years for a giant cell
tumor of the bone [7], and two post-menopausal women were
treated with an aromatase inhibitor and denosumab 120 mg
quarterly for 5 years [12, 13]. Extensive clinical assessment
ruled out any other pathology explaining the hypercalcemia.
The giant cell tumor of the bone was in remission [7], and in
the other cases, hypercalcemia persisted despite correction of
the newly diagnosed hyperthyroidism and antiaromatase dis-
continuation [13]. In all three cases, BTMs were markedly
elevated at the time of hypercalcemia. In one case, bone scin-
tigraphy performed in the oncological setting showed very
high whole body bone uptake [12], supporting the hypothesis
of excessive bone remodeling at denosumab discontinuation
as the cause of hypercalcemia. In these three cases, high doses
of denosumab may expla in the development of
hypercalcemia.
To date, two cases of hypercalcemia have been reported
after discontinuation of denosumab 60 mg every 6 months
given for osteoporosis [4, 14] without clinical consequences.
A 77-year-old woman with multiple risk factors for osteopo-
rosis, including decreased renal function, was hospitalized
6 months after the last denosumab injection due to dehydra-
tion secondary to diarrhea [14]. She had hypercalcemia and
suppressed PTH and was treated by rehydration; malignancy
was ruled out. A 67-year-old woman treated with denosumab
for 10 years developed asymptomatic hypercalcemia with
suppressed PTH 6 months after the last injection [4].
Bisphosphonates were given after the diagnosis of thoracic
SVFs, and serum calcium progressively decreased.
Secondary causes of osteoporosis were excluded. The authors
hypothesized that hypercalcemia developed due to the long
duration of denosumab treatment [4].
Hypercalcemia does not seem to be frequent at denosumab
discontinuation, and was excluded in some clinical trials and
case series [1, 2]. Calcemia values at denosumab discontinu-
ation are not mentioned in the other published case series nor
clinical trials. Hypercalcemia could be transiently present at
the onset of the rebound effect in people without other risk
factors for hypercalcemia, and may not have been observed, if
the serum calcium levels were measured after this transitional
period. The described patients may have experienced severe
hypercalcemia for reasons related either to the patient or their
pathology (baseline remodeling) or to the treatment
(denosumab dosage or duration), with some patients accumu-
lating several characteristics. Our patient was treated with
denosumab 60 mg twice yearly for osteoporosis for 3 years,
so neither denosumab dosage nor treatment duration can be at
the origin of the acute aggravation of the hypercalcemia. The
calcemia increased despite lower PTH under cinacalcet, in the
context of a dramatic increase in bone remodeling, suggesting
it was secondary to denosumab discontinuation.
Few data have been published on the use of denosumab in
primary hyperparathyroidism. Administration of denosumab
induces a transient increase in PTH values secondary to the
serum calcium decrease in post-menopausal osteoporotic
women with neither renal dysfunction nor primary hyperpara-
thyroidism [18]. Prolongation of denosumab treatment in pa-
tients with primary hyperparathyroidism, which implies re-
peated transient increases in PTH levels, does not seem to
have a stimulating effect on the PTH levels [19]. Very recent-
ly, a randomized double-blind trial compared denosumab,
denosumab plus cinacalcet, or placebo, given for 1 year, in
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45 patients with primary hyperparathyroidism [20].
Compared with the placebo group, BMD improved in both
groups receiving denosumab, despite an increase in PTH that
was not controlled by cinacalcet. At the end of the trial, pa-
tients were followed for only 4 weeks, so the consequences of
discontinuing denosumab were not assessed.
Conclusions
Hypercalcemia following denosumab discontinuation has
been well described in patients receiving high (oncological)
or frequent doses; this has been mainly shown in children, but
also in adults, as well as in patients treated with osteoporosis
doses. While severe hypercalcemia is probably uncommon, in
patients with pre-existent hypercalcemia or with an underlying
pathology associated to high bone remodeling, severe hyper-
calcemia may develop with variable delay after the last
denosumab injection. Systematic monitoring of serum calci-
um levels, i.e., before each denosumab injection, may be sug-
gested in the follow-up of at-risk patients. Although
denosumab seems to have a beneficial effect on BMD in pa-
tients with primary hyperparathyroidism, the risk of hypercal-
cemia upon its discontinuation should be taken into account
before its introduction. In any case, denosumab should not be
interrupted without further therapy.
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